Opinion|Videos|June 27, 2024
Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024
William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024.
Advertisement
Episodes in this series
- What current trends are you seeing in the world of breast cancer?How has the treatment of breast cancer evolved in recent history?
- Coming into ASCO 2024, what would you consider to be the largest unmet needs in the treatment and management of breast cancer?
- Provide the key recommendations and updates made in the 2024 NCCN guidelines for breast cancer.
- What have recommendationsfor the treatment and management of breast cancer changed since 2023?
Advertisement
Related to this article
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.
Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Advertisement
Advertisement
Trending on AJMC
1
Awareness Gaps Drive Narcolepsy, IH Delays: Logan Schneider, MD
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Administrative Burden Keeps Clinicians From Bedside: Amy Morris, MD
4
International Panel Agrees on Framework for Tapering Psoriasis Biologics
5